-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 28, French Minister of Industry Agnes Pannier-Runacher stated that the single-dose COVID-19 vaccine of the US drugmaker Johnson & Johnson may be approved for use in the EU in early March, and the European Medicines Agency (EMA) is also evaluating information on the Johnson & Johnson vaccine.
.
At the same time, it was pointed out that if the EU obtains approval in early March, it can launch the vaccine at the end of March or early April.
The EU hopes to receive 600 million doses of vaccine by the end of June.
So far, France has vaccinated 1.
5 million people.
The French Ministry of Health plans to vaccinate 15 million high-risk populations across France by June.
Verywellhealth Johnson Vaccine (Ad26.
COV2.
S) is studied as a single-dose and double-dose vaccine based on adenovirus.
It is an experimental viral vector vaccine that uses weakened live pathogen (adenovirus) as a recombinant vaccine for delivery of COVID-19 The delivery method (carrier).
Recombinant vaccines use a small piece of genetic material in a virus to trigger an immune response.
The genetic material of COVID-19 does not replicate in the body and can target specific viral fragments.
Moreover, recombinant vaccines are common and generally safe.
They can be vaccinated in people with chronic health problems or weakened immune systems.
On January 29 this year, Johnson & Johnson of New Jersey announced the main efficacy and safety data of a multi-country phase 3 clinical trial.
The data is based on randomized, placebo-controlled studies conducted in South Africa, certain countries in South America, Mexico and the United States, and included a total of Of the 43,783 participants, 21,895 of the participants were vaccinated.
The data shows that all the primary and secondary indicators have been met, which is also the primary safety and effectiveness data.
The multinational phase 3 study aims to evaluate the effectiveness and safety of Janssen COVID-19 candidate vaccine in protecting moderate to severe COVID-19.
The common primary endpoints are 14 days and 28 days after vaccination.
Among all participants from different regions, including those infected with newly emerging virus variants, 28 days after vaccination, the overall effective rate of COVID-19 candidate vaccines in preventing moderate to severe COVID-19 66%.
The onset of protection was observed as early as the 14th day after vaccination.
At 28 days after vaccination, the level of protection against moderate to severe COVID-19 infection is 72% in the United States, 66% in Latin America, and 57% in South Africa.
Currently, there is no data to determine how long the vaccine will provide protection.
If authorized, the Johnson & Johnson single-dose vaccine candidate drug is estimated to remain stable at -20°C (-4°F) for two years, of which at least three months can be at 2-8°C (36°F- 46°F).
The company will use the same cold chain technology used to transport other innovative drugs today to transport vaccines.
At present, it seems that the protection of Johnson & Johnson vaccine is not as good as Pfizer and Moderna's two-injection regimen.
The latter's efficacy against all forms of COVID-19 of the classic coronavirus strain is about 95%.
Verywellhealth reported that on February 25, the island nation of Bahrain became the first country to approve the use of Johnson & Johnson vaccine.
It was approved for emergency use in the United States on February 27 and became the first adenovirus vector vaccine in the United States.
At a previous press conference, the US Food and Drug Administration (FDA) stated that this single-dose vaccine is very effective in preventing severe COVID-19, including against newer variants of the virus.
It is expected that 4 million doses will be distributed to states in the United States as early as March 1.
By the end of March, it is estimated that 20 million doses will be provided to the United States, and 100 million doses will be provided by the summer.
The company's goal is to produce approximately 1 billion doses of vaccine globally by the end of this year.
Source of the original text: https:// For more information, please click to read the original text and download the Metz Medical APP~
.
At the same time, it was pointed out that if the EU obtains approval in early March, it can launch the vaccine at the end of March or early April.
The EU hopes to receive 600 million doses of vaccine by the end of June.
So far, France has vaccinated 1.
5 million people.
The French Ministry of Health plans to vaccinate 15 million high-risk populations across France by June.
Verywellhealth Johnson Vaccine (Ad26.
COV2.
S) is studied as a single-dose and double-dose vaccine based on adenovirus.
It is an experimental viral vector vaccine that uses weakened live pathogen (adenovirus) as a recombinant vaccine for delivery of COVID-19 The delivery method (carrier).
Recombinant vaccines use a small piece of genetic material in a virus to trigger an immune response.
The genetic material of COVID-19 does not replicate in the body and can target specific viral fragments.
Moreover, recombinant vaccines are common and generally safe.
They can be vaccinated in people with chronic health problems or weakened immune systems.
On January 29 this year, Johnson & Johnson of New Jersey announced the main efficacy and safety data of a multi-country phase 3 clinical trial.
The data is based on randomized, placebo-controlled studies conducted in South Africa, certain countries in South America, Mexico and the United States, and included a total of Of the 43,783 participants, 21,895 of the participants were vaccinated.
The data shows that all the primary and secondary indicators have been met, which is also the primary safety and effectiveness data.
The multinational phase 3 study aims to evaluate the effectiveness and safety of Janssen COVID-19 candidate vaccine in protecting moderate to severe COVID-19.
The common primary endpoints are 14 days and 28 days after vaccination.
Among all participants from different regions, including those infected with newly emerging virus variants, 28 days after vaccination, the overall effective rate of COVID-19 candidate vaccines in preventing moderate to severe COVID-19 66%.
The onset of protection was observed as early as the 14th day after vaccination.
At 28 days after vaccination, the level of protection against moderate to severe COVID-19 infection is 72% in the United States, 66% in Latin America, and 57% in South Africa.
Currently, there is no data to determine how long the vaccine will provide protection.
If authorized, the Johnson & Johnson single-dose vaccine candidate drug is estimated to remain stable at -20°C (-4°F) for two years, of which at least three months can be at 2-8°C (36°F- 46°F).
The company will use the same cold chain technology used to transport other innovative drugs today to transport vaccines.
At present, it seems that the protection of Johnson & Johnson vaccine is not as good as Pfizer and Moderna's two-injection regimen.
The latter's efficacy against all forms of COVID-19 of the classic coronavirus strain is about 95%.
Verywellhealth reported that on February 25, the island nation of Bahrain became the first country to approve the use of Johnson & Johnson vaccine.
It was approved for emergency use in the United States on February 27 and became the first adenovirus vector vaccine in the United States.
At a previous press conference, the US Food and Drug Administration (FDA) stated that this single-dose vaccine is very effective in preventing severe COVID-19, including against newer variants of the virus.
It is expected that 4 million doses will be distributed to states in the United States as early as March 1.
By the end of March, it is estimated that 20 million doses will be provided to the United States, and 100 million doses will be provided by the summer.
The company's goal is to produce approximately 1 billion doses of vaccine globally by the end of this year.
Source of the original text: https:// For more information, please click to read the original text and download the Metz Medical APP~
